Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FORT LAUDERDALE, Fla., April 10, 2018 -- Shanghai HEP Pharma Co. LTD, a research and development company focused on developing innovative drugs for hepatitis B, has signed a new agreement with OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology. Under the agreement, Shanghai HEP Pharma will use OmniComm’s TrialMaster EDC technology for a randomized Phase II/Phase III hepatitis B study.
The agreement represents OmniComm’s first TrialMaster deal in China. More than two years ago, OmniComm established a goal of developing a presence in the Chinese market, and to-date the company’s performance in that sector has met expectations. The expanded footprint in the Asia-Pacific region includes OmniComm’s first contract for TrialMaster® in Japan, along with 13 TrialOne® agreements in China.
As a system that is compliant with global industry standards, TrialMaster allows user organizations to ensure the quality and integrity of the data collected and managed during the entire study. TrialMaster also enables users to comply with the Chinese FDA’s new regulation and approval process for new drug development in China. TrialMaster’s ability to facilitate users’ compliance with CFDA’s regulations aimed at harmonizing local practices to global standards was also a key factor.
“From our research and development pipeline, we have developed this hepatitis B drug from the concept stage,” said Dr. Hongli Liu, CEO of Shanghai HEP Pharma. “This hepatitis B drug is a critical product for us, and we wanted to select a high quality and global standard EDC system to ensure our study is well managed. We had excellent experience using OmniComm’s Phase I system, Promasys®, which naturally led to TrialMaster, OmniComm’s Phase II/III EDC system. We look forward to working with OmniComm’s team on study build and are confident to hit First Patient In date on time.”
“We are very excited about our first deployment of TrialMaster in China, and it is with a highly innovative biotechnology company,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “We are delighted that we were selected in a highly competitive evaluation.”
About OmniComm Systems, Inc.
OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. For more information, visit www.omnicomm.com.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
[email protected]
